Efficacy of Imatinib Mesylate Treatment for a Patient with Rheumatoid Arthritis and Who Developed Chronic Myelogenous Leukemia.
10.4078/jrd.2011.18.2.118
- Author:
Hye Kyung JEON
1
;
Young Eun PARK
;
Sung Il KIM
;
Seong Hu PARK
;
Seung Hoon BAEK
;
Joung Wook LEE
;
Dong Woo HA
;
Hye Won LEE
;
Joo Seop CHUNG
;
Seung Hee LEE
;
Eun Yup LEE
Author Information
1. Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea. antibio1004@hanmail.net
- Publication Type:Case Report
- Keywords:
Rheumatoid arthritis;
Chronic myelogenous leukemia;
Imatinib mesylate
- MeSH:
Antirheumatic Agents;
Arthritis, Rheumatoid;
Benzamides;
Cytogenetics;
Female;
Hematologic Neoplasms;
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
Mesylates;
Methotrexate;
Middle Aged;
Piperazines;
Pyrimidines;
Thrombocytosis;
Imatinib Mesylate
- From:Journal of Rheumatic Diseases
2011;18(2):118-121
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Rheumatoid arthritis is associated with an increased risk of hematological malignancy as a result of the RA itself or its treatment. We report here on an unusual case of a 55-year-old female with long-standing rheumatoid arthritis and who was treated with low dose methotrexate and hydrochloroquine. She was diagnosed with chronic myelogenous leukemia that manifested with severe thrombocytosis and basophilia, and this was treated with imatinib mesylate. After 6 months, she achieved a complete cytogenetic response of the CML and a complete resolution of all the RA symptoms without DMARDs.
